title: Acetyl-L-carnitine in hepatic encephalopathy.
abstract: Hepatic encephalopathy is a common complication of hepatic cirrhosis. The clinical diagnosis is based on two concurrent types of symptoms: impaired mental status and impaired neuromotor function. Impaired mental status is characterized by deterioration in mental status with psychomotor dysfunction, impaired memory, and increased reaction time, sensory abnormalities, poor concentration, disorientation and coma. Impaired neuromotor function include hyperreflexia, rigidity, myoclonus and asterixis. The pathogenesis of hepatic encephalopathy has not been clearly defined. The general consensus is that elevated levels of ammonia and an inflammatory response work in synergy to cause astrocyte to swell and fluid to accumulate in the brain which is thought to explain the symptoms of hepatic encephalopathy. Acetyl-L-carnitine, the short-chain ester of carnitine is endogenously produced within mitochondria and peroxisomes and is involved in the transport of acetyl-moieties across the membranes of these organelles. Acetyl-L-carnitine administration has shown the recovery of neuropsychological activities related to attention/concentration, visual scanning and tracking, psychomotor speed and mental flexibility, language short-term memory, attention, and computing ability. In fact, Acetyl-L-carnitine induces ureagenesis leading to decreased blood and brain ammonia levels. Acetyl-L-carnitine treatment decreases the severity of mental and physical fatigue, depression cognitive impairment and improves health-related quality of life. The aim of this review was to provide an explanation on the possible toxic effects of ammonia in HE and evaluate the potential clinical benefits of ALC.
authors: International Ph.D. Program in Neuropharmacology, University of Catania, Catania, Italy. m.malaguarnera@email.it
authors: Michele
authors: M
authors: Malaguarnera
mesh_terms: D000108:Acetylcarnitine / Q000378:metabolism* / Q000627:therapeutic use*; D000818:Animals; D006501:Hepatic Encephalopathy / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D022124:Hyperammonemia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000108:Acetylcarnitine
references: Metab Brain Dis. 2005 Dec;20(4):275-83
references: 16382338
references: J Neurochem. 2010 Aug;114(3):820-31
references: 20477950
references: Pediatr Neurol. 1986 Mar-Apr;2(2):90-4
references: 3508684
references: Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):365-78
references: 20528123
references: Nutr Metab (Lond). 2010 Apr 16;7:30
references: 20398344
references: Metab Brain Dis. 2004 Dec;19(3-4):313-29
references: 15554424
references: Neuroscience. 2010 Feb 17;165(4):1345-52
references: 19925851
references: World J Gastroenterol. 2011 Oct 21;17(39):4414-20
references: 22110268
references: Neurochem Int. 2012 Jun;60(7):697-706
references: 21989389
references: Scand J Gastroenterol. 2011 Jun;46(6):750-9
references: 21443422
references: Metab Brain Dis. 2011 Dec;26(4):281-9
references: 21870121
references: Metab Brain Dis. 2002 Dec;17(4):389-97
references: 12602515
references: Neurochem Int. 2012 Sep;61(4):575-80
references: 22285152
references: Clin Liver Dis. 2012 Feb;16(1):7-26
references: 22321462
references: Brain Res. 1998 Jun 15;796(1-2):75-81
references: 9689456
references: Eur J Gastroenterol Hepatol. 2009 Jul;21(7):762-70
references: 19357525
references: Am J Clin Nutr. 2011 Apr;93(4):799-808
references: 21310833
references: Hepatology. 1997 Mar;25(3):551-6
references: 9049197
references: Dig Dis Sci. 2008 Nov;53(11):3018-25
references: 18357530
references: J Bioenerg Biomembr. 2004 Aug;36(4):347-52
references: 15377870
references: FASEB J. 1992 Dec;6(15):3379-86
references: 1464372
references: Metabolism. 1993 Aug;42(8):1039-46
references: 8102193
references: J Gen Intern Med. 2008 Feb;23(2):210-3
references: 18080167
references: J Cell Biochem. 2000 Sep 18;80(1):1-10
references: 11029749
references: Dig Dis Sci. 2006 Dec;51(12):2242-7
references: 17080254
references: Metab Brain Dis. 2009 Mar;24(1):69-80
references: 19085094
references: J Pharmacol Exp Ther. 1996 Oct;279(1):194-9
references: 8858993
references: Neurochem Int. 2009 Jul-Aug;55(1-3):113-8
references: 19428814